299 related articles for article (PubMed ID: 21843936)
1. 3D QSAR and docking study of flavone derivatives as potent inhibitors of influenza H1N1 virus neuraminidase.
Gao L; Zu M; Wu S; Liu AL; Du GH
Bioorg Med Chem Lett; 2011 Oct; 21(19):5964-70. PubMed ID: 21843936
[TBL] [Abstract][Full Text] [Related]
2. Docking and 3D QSAR study of thiourea analogs as potent inhibitors of influenza virus neuraminidase.
Sun J; Cai S; Mei H; Li J; Yan N; Wang Y
J Mol Model; 2010 Dec; 16(12):1809-18. PubMed ID: 20213331
[TBL] [Abstract][Full Text] [Related]
3. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
[TBL] [Abstract][Full Text] [Related]
4. Docking and 3D-QSAR investigations of pyrrolidine derivatives as potent neuraminidase inhibitors.
Sun J; Mei H
Chem Biol Drug Des; 2012 May; 79(5):863-8. PubMed ID: 22251826
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel zanamivir derivatives as potent neuraminidase inhibitors.
Cheng LP; Wang TC; Yu R; Li M; Huang JW
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3622-3629. PubMed ID: 30389293
[TBL] [Abstract][Full Text] [Related]
6. Molecular docking and QSAR studies on substituted acyl(thio)urea and thiadiazolo [2,3-alpha] pyrimidine derivatives as potent inhibitors of influenza virus neuraminidase.
Sun J; Cai S; Mei H; Li J; Yan N; Wang Q; Lin Z; Huo D
Chem Biol Drug Des; 2010 Sep; 76(3):245-54. PubMed ID: 20626407
[TBL] [Abstract][Full Text] [Related]
7. QSAR study of flavonoids and biflavonoids as influenza H1N1 virus neuraminidase inhibitors.
Mercader AG; Pomilio AB
Eur J Med Chem; 2010 May; 45(5):1724-30. PubMed ID: 20116898
[TBL] [Abstract][Full Text] [Related]
8. In vitro antiviral effects and 3D QSAR study of resveratrol derivatives as potent inhibitors of influenza H1N1 neuraminidase.
Li C; Fang JS; Lian WW; Pang XC; Liu AL; Du GH
Chem Biol Drug Des; 2015 Apr; 85(4):427-38. PubMed ID: 25185493
[TBL] [Abstract][Full Text] [Related]
9. Pharmacophore modeling, quantitative structure-activity relationship analysis, and shape-complemented in silico screening allow access to novel influenza neuraminidase inhibitors.
Abu Hammad AM; Taha MO
J Chem Inf Model; 2009 Apr; 49(4):978-96. PubMed ID: 19341295
[TBL] [Abstract][Full Text] [Related]
10. Structure-based and multiple potential three-dimensional quantitative structure-activity relationship (SB-MP-3D-QSAR) for inhibitor design.
Du QS; Gao J; Wei YT; Du LQ; Wang SQ; Huang RB
J Chem Inf Model; 2012 Apr; 52(4):996-1004. PubMed ID: 22480344
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of 4-alkyl-2-amino(acetamino)-6-aryl-1,3-thiazine derivatives as influenza neuraminidase inhibitors.
Li W; Xia L; Hu A; Liu A; Peng J; Tan W
Arch Pharm (Weinheim); 2013 Sep; 346(9):635-44. PubMed ID: 23926081
[TBL] [Abstract][Full Text] [Related]
12. Molecular docking, 3D-QSAR studies, and in silico ADME prediction of p-aminosalicylic acid derivatives as neuraminidase inhibitors.
Zhang J; Shan Y; Pan X; Wang C; Xu W; He L
Chem Biol Drug Des; 2011 Oct; 78(4):709-17. PubMed ID: 21752201
[TBL] [Abstract][Full Text] [Related]
13. Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus.
Wang SQ; Du QS; Huang RB; Zhang DW; Chou KC
Biochem Biophys Res Commun; 2009 Aug; 386(3):432-6. PubMed ID: 19523442
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the anti-neuraminidase activity of the traditional Chinese medicines and determination of the anti-influenza A virus effects of the neuraminidase inhibitory TCMs in vitro and in vivo.
Tian L; Wang Z; Wu H; Wang S; Wang Y; Wang Y; Xu J; Wang L; Qi F; Fang M; Yu D; Fang X
J Ethnopharmacol; 2011 Sep; 137(1):534-42. PubMed ID: 21699971
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of novel oseltamivir derivatives as potent neuraminidase inhibitors.
Wang Z; Cheng LP; Zhang XH; Pang W; Li L; Zhao JL
Bioorg Med Chem Lett; 2017 Dec; 27(24):5429-5435. PubMed ID: 29141777
[TBL] [Abstract][Full Text] [Related]
16. Correlation analyses on binding affinity of sialic acid analogues and anti-influenza drugs with human neuraminidase using ab initio MO calculations on their complex structures--LERE-QSAR analysis (IV).
Hitaoka S; Matoba H; Harada M; Yoshida T; Tsuji D; Hirokawa T; Itoh K; Chuman H
J Chem Inf Model; 2011 Oct; 51(10):2706-16. PubMed ID: 21870866
[TBL] [Abstract][Full Text] [Related]
17. Understanding of known drug-target interactions in the catalytic pocket of neuraminidase subtype N1.
Malaisree M; Rungrotmongkol T; Decha P; Intharathep P; Aruksakunwong O; Hannongbua S
Proteins; 2008 Jun; 71(4):1908-18. PubMed ID: 18175324
[TBL] [Abstract][Full Text] [Related]
18. 3D-quantitative structure-activity relationship and antiviral effects of curcumin derivatives as potent inhibitors of influenza H1N1 neuraminidase.
Lai Y; Yan Y; Liao S; Li Y; Ye Y; Liu N; Zhao F; Xu P
Arch Pharm Res; 2020 May; 43(5):489-502. PubMed ID: 32248350
[TBL] [Abstract][Full Text] [Related]
19. Multiple field three dimensional quantitative structure-activity relationship (MF-3D-QSAR).
Du QS; Huang RB; Wei YT; Du LQ; Chou KC
J Comput Chem; 2008 Jan; 29(2):211-9. PubMed ID: 17559075
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological activity of thiazole derivatives as novel influenza neuraminidase inhibitors.
Liu Y; Zhang L; Gong J; Fang H; Liu A; Du G; Xu W
J Enzyme Inhib Med Chem; 2011 Aug; 26(4):506-13. PubMed ID: 21143042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
